所有图片(1)

主要文件

查看所有文档

Y0000554

地高辛

Name: 地高辛
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

异羟基洋地黄毒苷

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₄₁H₆₄O₁₄

CAS号:

20830-75-5

分子量:

780.94

Beilstein:

77011

MDL號碼:

MFCD00003674

分類程式碼代碼:

41116107

PubChem物質ID:

329831017

NACRES:

NA.24

推荐产品

Slide 1 of 10

1 of 10

D1900000

地高辛

Y0000640

地高辛配基

Supelco

04599

地高辛

Supelco

PHR1771

地高辛

PHL82573

毛花苷C

Supelco

D6003

地高辛

USP

1200000

地高辛

Sigma-Aldrich

SML2800

海葱次苷

Sigma-Aldrich

282197

香芹酚

Sigma-Aldrich

D9404

洋地黄毒苷配基

等級

pharmaceutical primary standard

API 家族

digoxin

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]3[C@@H](O)C[C@@H](O[C@@H]3C)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4

InChI

1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1

InChI 密鑰

LTMHDMANZUZIPE-PUGKRICDSA-N

基因資訊

human ... ATP1A1(476) , ATP1A2(477) , ATP1A3(478) , ATP1A4(480) , ATP1B1(481) , ATP1B2(482) , ATP1B3(483) , FXYD2(486)

正在寻找类似产品? 访问产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Digoxin for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

一种强心苷，P-糖蛋白的底物，上调 Pgp 表达和下调 SXR（固醇类异生物受体）。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

訊號詞

Danger

危險聲明

H300,H331,H373

防範說明

P260 - P264 - P271 - P301 + P310 - P304 + P340 + P311 - P314

危險分類

Acute Tox. 2 Oral - Acute Tox. 3 Inhalation - STOT RE 2

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類（WGK）

WGK 3

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.

Murilo Rodrigues et al.

Diabetes, 62(11), 3863-3873 (2013-07-26)

In proliferative diabetic retinopathy (PDR), retinal ischemia promotes neovascularization (NV), which can lead to profound vision loss in diabetic patients. Treatment for PDR, panretinal photocoagulation, is inherently destructive and has significant visual consequences. Therapies targeting vascular endothelial growth factor (VEGF)

Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).

Ryozo Nagai et al.

Circulation journal : official journal of the Japanese Circulation Society, 77(4), 908-916 (2013-03-19)

A rapid heart rate (HR) during atrial fibrillation (AF) and atrial flutter (AFL) in left ventricular (LV) dysfunction often impairs cardiac performance. The J-Land study was conducted to compare the efficacy and safety of landiolol, an ultra-short-acting β-blocker, with those

Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management?

Jocasta Ball et al.

Heart (British Cardiac Society), 99(8), 542-547 (2013-01-15)

We examined cognitive function in older hospitalised patients with chronic atrial fibrillation (AF). A prospective substudy of a multicentre randomised trial of an AF-specific disease management intervention (the Standard versus Atrial Fibrillation spEcific managemenT studY; SAFETY). Three tertiary referral hospitals

Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.

Susanne Johansson et al.

Clinical pharmacokinetics, 53(9), 837-847 (2014-08-15)

Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. We investigated potential drug-drug interactions between vandetanib and metformin

Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.

Mihai Gheorghiade et al.

European heart journal, 34(20), 1489-1497 (2013-04-18)

Digoxin is recommended for long-term rate control in paroxysmal, persistent, and permanent atrial fibrillation (AF). While some analyses suggest an association of digoxin with a higher mortality in AF, the intrinsic nature of this association has not been examined in

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

主要文件

地高辛